Ranking Profile - Chengdu Kanghong Pharmaceuticals Group Co Ltd
Introduction
Chengdu Kanghong Pharmaceuticals Group Co Ltd (Kanghong Pharmaceuticals) focuses on the development, manufacturing and marketing of Chinese medicines, chemical drugs, and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal, and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Yiqing, Keluoxin, Yitanning, and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs, and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China.
Company info
Country (HQ): | China |
Sector: | Pharmaceuticals and Healthcare |
Market Cap (US$ m): | 2,394 |
Revenue (US$ m): | 504 (2022) |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Chengdu Kanghong Pharmaceuticals Group Co Ltd
China
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release